Shackelford Pharma

Shackelford Pharma

Growth Stage

PIONEERING FOR PATIENTS

PIONEERING FOR PATIENTS

Overview

Raised this Round: Raised: $833,148

Total Commitments ($USD)

Platform

Dealmaker Securities

Start Date

12/11/2022

Close Date

Not Provided

Min. Goal
$1,500
Max. Goal
$12,520,000
Min. Investment

$1,500

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$1.50

Pre-Money Valuation

$68,195,651

Year Founded

2018

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Location

Vancouver, British Columbia

Business Type

Growth

Shackelford Pharma is raising funds independently through Reg A+ crowdfunding with DealMaker Securities as the Broker-Dealer. It is a biopharmaceutical company dedicated to developing medicines for neurological diseases. The company is currently developing SP1707 as its first drug candidate as a long-acting cannabinoid formulation for patients suffering from seizures. Mark Godsy and Dr. Alan Shackelford founded Shackelford Pharma in 2018. The current crowdfunding campaign has a maximum target of $12.5 million. The campaign proceeds will be used for research and development and general working capital.

Balance Sheet

Cash and Cash Equivalents

$6,143,513

Accounts and Notes Receivable

$54,611

Total Assets

$6,411,228

Accounts Payable & Accrued Liabilities

$403,212

Long Term Debt

$0

Total Liabilities

$6,411,228

Total Stockholders' Equity

$6,008,016

Total Liabilities and Equity

$6,411,228

Statement of Comprehensive Income Information

Depreciation and Amortization

$6,552

Net Income

$-3,520,134

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: Dale Matheson Carr-Hilton Labonte LLP
Financials as of: 12/11/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Shackelford Pharma 12/13/2023 Dealmaker Securities $68,195,651 $833,148 Equity - Common Funded RegA+
Shackelford Pharma 08/19/2021 Dalmore Group $37,595,931 $9,303,845 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Shackelford Pharma on DealMaker Securities 2022
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $68,195,651
Price per Share: $1.50

Follow company

Follow Shackelford Pharma on DealMaker Securities 2022

Buy Shackelford Pharma's Deal Report

Warning: according to the close date for this deal, Shackelford Pharma may no longer be accepting investments.

Shackelford Pharma Deal Report

Get KingsCrowd’s comprehensive report on Shackelford Pharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Shackelford Pharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Shackelford Pharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge